GPC Biotech To Resubmit Orplatna With Overall Survival Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Company announces it will withdraw the NDA for satraplatin for prostate cancer based on outcome of advisory committee meeting.
You may also be interested in...
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Sanofi-Aventis’ Jevtana is notable for its 11-week expedited review, which made it as the speediest approval of 2010.
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Sanofi-Aventis’ Jevtana is notable for its 11-week expedited review, which made it as the speediest approval of 2010.
GPC Biotech Plans Restructuring To Cut Costs Following SPARC Failure
German firm is planning workforce reductions after satraplatin did not show a survival benefit in prostate cancer patients